IBRX - ImmunityBio gains as bladder cancer therapy undergoes FDA review
2023-10-26 12:48:21 ET
More on ImmunityBio
- ImmunityBio: The CRL Makes It Riskier Than Ever
- ImmunityBio: Ongoing Dilution And Regulatory Uncertainties Blur Investment Prospects
- ImmunityBio extends gains on surging volumes after regulatory update
- ImmunityBio announces $470M equity and debt financing from founder Patrick Soon-Shiong and Nant Entities
- Seeking Alpha’s Quant Rating on ImmunityBio
For further details see:
ImmunityBio gains as bladder cancer therapy undergoes FDA review